Born to Clot: The European Burden

The Prevalence of the Prothrombin (F2) 20210G>A Mutation in a Cohort of Sri Lankan Patients with Thromboembolic Disorders

“…The prevalence in these countries is similar to that reported in South European countries which is approximately 3 to 24 % in VTE patients and 1 to 12 % in the general population [11]. Previous studies have reported the absence of this mutation among healthy controls in Asian populations in China, Japan, Korea, Mongolia, Taiwan, Indonesia, Burma, Cambodia, Thailand, Taiwan, Vietnam, Hong Kong, Pakistan and Bangladesh [11,12,[15][16][17][18][19][21][22][23][24][25], while in India it was reported to be between 0 to 0.6 % [11,19,22,[25][26][27][28][29]. Among the VTE patients in China, Korea, and Taiwan, the prevalence of the mutation carriers was 0 % [11,12,[15][16][17][19][20][21][22][23][24].…”

“…Even in India, only one study has reported a prevalence of 0.6 % among healthy controls [22], while some other studies have reported it as 0 % [11,19,[25][26][27][28][29]. The mutation has not been reported among Indian patients with venous thrombo-embolism [11,19,22,[25][26][27][28][29]. These studies suggest that the F2 20210G[A mutation may not be a significant genetic risk factor predisposing to inherited thrombophilia in those populations.…”

“…Furthermore, the prevalence of the mutation in those populations is higher among patients with thromo-embolic disorders than in healthy controls [11,12]. However, in many Asian countries it is reported to be absent in both the healthy controls as well as among patients with thrombo-embolic disorders [11,12,[15][16][17][18][19][21][22][23][24][25]. Even in India, only one study has reported a prevalence of 0.6 % among healthy controls [22], while some other studies have reported it as 0 % [11,19,[25][26][27][28][29].…”

“…However, in many Asian countries it is reported to be absent in both the healthy controls as well as among patients with thrombo-embolic disorders [11,12,[15][16][17][18][19][21][22][23][24][25]. Even in India, only one study has reported a prevalence of 0.6 % among healthy controls [22], while some other studies have reported it as 0 % [11,19,[25][26][27][28][29]. The mutation has not been reported among Indian patients with venous thrombo-embolism [11,19,22,[25][26][27][28][29].…”

“…Among the VTE patients in China, Korea, and Taiwan, the prevalence of the mutation carriers was 0 % [11,12,[15][16][17][19][20][21][22][23][24]. Even among the Indian VTE patients, the prevalence was 0 % [11,19,22,[25][26][27][28][29]. Hence it is likely that the F2 20210G[A mutation occurs in a very low frequency in Asian and other non Caucasian populations [11,12].…”